Anti-MVK Polyclonal Antibody for WB, ELISA - Q03426

Core Product Specifications and Parameters

Biological Background: MVK Function and Localization

• Mevalonate kinase (MVK) is an essential enzyme in the mevalonate pathway, catalyzing the ATP-dependent phosphorylation of mevalonate to form mevalonate 5-phosphate, a critical step in cholesterol and isoprenoid biosynthesis. Related references: PMID:11278915 PMID:18302342 PMID:9325256
• The enzyme belongs to the galactokinase family and requires magnesium ions for its kinase activity.
• MVK is primarily localized in the cytoplasm and peroxisomes, consistent with its role in early steps of cholesterol biosynthesis.
• Genetic mutations in MVK are associated with human diseases, including mevalonate kinase deficiency (MKD) which manifests as hyper-IgD syndrome and mevalonic aciduria, as well as porokeratosis (POROK3).
• Consistent with its metabolic role, MVK is classified under lipid biosynthesis, steroid biosynthesis, and transferase activity, and is a proteomics-verified reference proteome component.

Experimental Guidance and Technical Tips

• The immunogen used to generate this antibody covers amino acids 40–300 of human MVK, representing a large portion of the protein; consider validating the antibody in your specific experimental system.
• For Western blotting, a band around 42 kDa is expected; include a positive control such as human liver or kidney lysate, which express MVK.
• For ELISA applications, coating with recombinant MVK protein and testing a range of antibody dilutions may help optimize the assay.
• Because this is a polyclonal antibody, it may exhibit batch-to-batch variability; always titrate and validate for each new lot.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio supports diagnostic manufacturers, laboratories, and research institutes with comprehensive access to IVD raw materials. This anti-MVK polyclonal antibody is part of our portfolio for cholesterol metabolism research and assay development. Beyond this product, we can supply validated antibody pairs, optimized monoclonal/polyclonal antibodies, bulk ancillary reagents, and sourcing of rare targets to accelerate your concept-to-clinic journey.